Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Windtree Therapeutics, Inc. - Common Stock (NQ:WINT)

0.5252 +0.0052 (+1.00%)
Streaming Delayed Price Updated: 10:56 AM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Windtree Therapeutics, Inc. - Common Stock

Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Closes Strategic Acquisition, Expanding Nisk Footprint – More Stocks Inside
Via AB Newswire
Synergy CHC (NASDAQ: SNYR) Taps Coca-Cola Exec to Accelerate Global Expansion of “FOCUSfactor®” Energy Drink – More Stocks Moving Inside
Via AB Newswire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
Windtree Therapeutics Inc. (NASDAQ: WINT) Near the Top of Equities by Percentage Gain on 4/17
Via Investor Brand Network
Windtree Therapeutics Inc. (NASDAQ: WINT) Near the Top of Equities by Percentage Gain on 3/30
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
Sidoti Events, LLC's Virtual November Micro-Cap Conference
Via ACCESSWIRE
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
Via ACCESSWIRE
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
Via ACCESSWIRE
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
Via ACCESSWIRE
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
Via ACCESSWIRE
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
Via ACCESSWIRE
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
Via ACCESSWIRE
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That
Via ACCESSWIRE
Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure
Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders. 
Via Spotlight Growth
Topics Intellectual Property
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are... 
From Access to Giving
Via AccessWire
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting... 
From Access to Giving
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.